For patients with relapsing multiple sclerosis, switching from oral therapies to subcutaneous monthly administration of the anti-CD20 monoclonal antibody ofatumumab led to over a 98 percent reduction of Gd+ T1 lesions on MRI at 96 weeks.
For patients with relapsing multiple sclerosis, switching from oral therapies to subcutaneous monthly administration of the anti-CD20 monoclonal antibody ofatumumab led to over a 98 percent reduction of Gd+ T1 lesions on MRI at 96 weeks.